Eli Lilly Reports Deal To Buy Dermira For $1.1BHomeMailNewsFinanceSportsEntertainmentSearchMobileMoreYahooSearchNo matching results for ''Tip: Try a valid symbol or a specific company name for relevant resultsSign inMailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets open in 9 hrs 18 minsS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Eli Lilly Reports Deal To Buy Dermira For $1.1BTanzeel AkhtarBenzingaJanuary 10, 2020ReblogShareTweetShareEli Lilly (NYSE: LLY) announced Friday it will acquire Dermira, Inc. (NASDAQ: DERM) for $18.75 per share, around $1.1 billion, in an all-cash transaction.Dermira is a biopharmaceutical company developing new therapies for chronic skin conditions."People suffering from moderate-to-severe atopic dermatitis have significant unmet treatment needs, and we are excited about the potential that lebrikizumab has to help these patients," said Patrik Jonsson, Lilly senior vice president and president of Lilly Bio-Medicines. "The acquisition of Dermira is consistent with Lilly's strategy to augment our own internal research by acquiring clinical phase assets in our core therapeutic areas and leveraging our development expertise and commercial infrastructure to bring new medicines to patients."The transaction is expected to close by the end of the first-quarter of 2020. The purchase price represents a premium of 86% to the 60-day volume-weighted average trading price of Dermira's stock ending on Jan 9., the last trading day before the announcement of the transaction.Certain Dermira stockholders, owning approximately 13% of Dermira's outstanding common stock, have agreed to tender their shares in the tender offer.Dermira shares traded higher by 2.4% to $18.77 at time of publication.Related Links:Eli Lilly Reports Mixed Q3 Earnings, Raises GuidanceEli Lilly Announces Positive Results For Emgality0See more from BenzingaPrince Harry And Meghan Seek Financial Independence: How Do British Royals Make Their Money?Is Elon Musk's Girlfriend Grimes Pregnant?Apple's Strong Holiday Sales Boost Shares© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoCrocs CEO explains its major turnaroundYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoIcahn Proposed Buying HP If It Didn’t Pursue Xerox MergerBloombergWhat the GM strike means for the U.S. economyYahoo FinanceWhy negative interest rates are 'seriously dangerous': strategistYahoo FinanceAurora Cannabis tumbles after double downgradeYahoo Finance VideoCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoViacomCBS Layoffs Underway As Re-Merged Company Continues To Cut CostsDeadlineLoan growth will be a 'critical factor' in upcoming bank earnings: AnalystYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceU.S. airlines suspend flights over coronavirus fearsYahoo Finance VideoBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo Finance